

Pfizer Hosts Annual Meeting Of Shareholders

Wednesday, April 24, 2013 - 10:16pm

Declares 24-Cent Second-Quarter 2013 Dividend

"In 2013, we are continuing to take actions to increase shareholder value, including our dividend increase announced in December 2012, our continued share repurchase activity and the successful completion of the IPO of a 19.8% interest in Zoetis in February 2013."

([BUSINESS WIRE](#))--The board of directors of Pfizer Inc. today declared a 24-cent second-quarter 2013 dividend on the company's common stock, payable June 4, 2013, to shareholders of record at the close of business on May 10, 2013. The second-quarter 2013 cash dividend will be the 298th consecutive quarterly dividend paid by Pfizer.

"Through dividends and share repurchases, we returned approximately \$15 billion to our shareholders in 2012," said Ian Read, chairman and chief executive officer, Pfizer. "In 2013, we are continuing to take actions to increase shareholder value, including our dividend increase announced in December 2012, our continued share repurchase activity and the successful completion of the IPO of a 19.8% interest in Zoetis in February 2013."

Preliminary results from the meeting indicate that the company's 13 continuing directors were re-elected to one-year terms and that shareholders ratified the selection of KPMG LLP as Pfizer's independent registered public accounting firm for the 2013 fiscal year. In addition, shareholders voted in support of a board-sponsored proposal to approve, on an advisory basis, the compensation of the company's named executive officers.

In other voting, two shareholder proposals were not approved by the shareholders.

The final results are subject to verification by the independent election inspectors. The final results will be reported in a Form 8-K to be filed by Pfizer with the Securities and Exchange Commission in the next few days.

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.

DISCLOSURE NOTICE: The information contained in this release is as of April 25, 2013. The Company assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments.

This release contains forward-looking information about the Company's actions to increase shareholder value, including with respect to dividends and share repurchases, that involves substantial risks and uncertainties. A description of these risks and uncertainties can be found in the Company's Annual Report on Form 10-K/A for the fiscal year ended December 31, 2012 and in its reports on Forms 10-Q and 8-K.

Pfizer Inc. Media: Joan Campion, 212-733-2798 or Investor: Suzanne Harnett, 212-733-8009